Physician profile
Eric Dein
NPI 1447599501
$5,215.89
in general payments reported to CMS, 2019-2025
28 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $630 · 2023: $985 · 2024: $1,797 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,252 · Education: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,252.23 |
| Education | $224.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,122.38 | 2021-2025 | Evenity, Enbrel, Prolia |
| Pfizer INC. | $944.70 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $687.70 | 2024-2025 | |
| Abbvie INC. | $646.61 | 2021-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $437.11 | 2024-2025 | Tremfya |
| Ucb, INC. | $288.21 | 2022-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $177.47 | 2021-2025 | Benlysta |
| Ferring Pharmaceuticals INC. | $112.47 | 2021-2024 | Euflexxa |
| Lilly USA, LLC | $107.09 | 2022-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $87.77 | 2024-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $68.13 | 2022-2024 | Acthar |
| Ani Pharmaceuticals, INC. | $65.96 | 2024-2025 | Purified Cortrophin Gel |
| Organon LLC | $64.79 | 2023-2025 | Hadlima, Renflexis |
| Sobi, INC | $58.25 | 2022-2024 | |
| Aurinia Pharma U.S., INC. | $58.05 | 2024 | Lupkynis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $54.05 | 2021-2025 | Saphnelo |
| Genzyme Corporation | $31.00 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $30.66 | 2024 | Arcalyst |
| Zimmer Biomet Holdings, INC. | $24.09 | 2023 | Gel-One Cross-Linked Hyaluronate |
| Radius Health, INC. | $22.25 | 2024 | Tymlos |
| Grifols USA, LLC | $19.54 | 2025 | Xembify |
| Invivyd INC | $19.00 | 2025 | Pemgarda |
| Celltrion USA INC. | $17.00 | 2023 | Yuflyma |
| Genentech USA, INC. | $16.99 | 2024 | Actemra |
| Alexion Pharmaceuticals, INC. | $14.68 | 2025 | Strensiq |
| Fresenius Kabi USA, LLC | $14.11 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.61 | 2024 | Cyltezo |
| Hikma Pharmaceuticals USA | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Dein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.